Table 3.
The Pharmacokinetic Parameters in Comparative Studies
| Author (Year) | Sample Size | Vancomycin Clearance (mL/min) | T1/2 of Vancomycin (h) | V (L) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hematologic Malignancies or Neutropenia | Control Group | P value | Hematologic Malignancies or Neutropenia | Control Group | P value | Hematologic Malignancies or Neutropenia | Control Group | P value | ||
| Neutropenic patients vs. non-neutropenic patients | ||||||||||
| Haeseker 201425 | 171 | 67 ± 26 | 50 ± 22 | <0.001 | – | – | – | 62 ± 32 | 56 ± 29 | 0.304 |
| 68 (subset of patients with hematologic malignancies) | 68 ± 26 | 53 ± 16 | 0.024 | – | – | – | 62 ± 32 | 59 ± 18 | 0.691 | |
| Choi 201723 | 1307 | – | – | – | 7.4 h (5.9–10.7 h) # | 8.9 h (6.9 −12.0 h)# | <0.0001 | – | – | – |
| Patients with hematologic malignancies vs. non-cancer patients | ||||||||||
| Al-Kofide 200924 | 31 | 110.1 ± 42 | 71.2 ± 22.2 | 0.005 | 8.6 ± 7.1 | 5.4 ± 1.9 | 0.111 | 70 ± 45 | 31.1 ± 8.3 | 0.002 |
| Izumisawa 201937 | 522 | 0.055 ± 0.017 L/h/kg | 0.051 ± 0.019 L/h/kg | <0.05 | 32.7 ± 13.0 | 37.1 ± 18.8 | <0.05 | 1.81 ± 0.57 L/kg | 1.84 ± 0.62 L/kg | >0.05 |
Notes: –, not reported; #, median (interquartile range).